In an effort to curb “unexpected and outrageous bills,” President Trump invited patients and others to the White House to discuss their experiences with such pricing, Kaiser Health News reported. The discussion is part of Trump’s overall goal to impact drug prices and transparency in healthcare.

Walgreens Boots Alliance has settled two fraud cases with the Department of Justice, shelling out $269.2 million. In both cases, which arose from whistleblowers, Walgreens admitted and accepted responsibility for conduct alleged by the government in its complaint under the False Claims Act.

The U.S. government shutdown, which is now the longest-running in history, could potentially harm consumers and undermine the stability of the Affordable Care Act healthcare insurance market, The Wall Street Journal reported.

As progressive Democrats increasingly push for universal healthcare, known as Medicare for all, support for such a plan is mixed when it comes to paying for it, according to a recent poll from the Kaiser Family Foundation.

The trade group for the U.S.'s top drugmakers spent a record amount—$27.5 million—on lobbying efforts in 2018, according to Bloomberg.

More industry groups are pushing back against an upcoming deadline for accountable care organizations (ACOs) to apply to the updated Medicare Shared Savings Program.

Medicare payments in 2019 aren’t likely to cover the cost of delivering care for two-thirds of medical practices, according to a survey from the Medical Group Management Association (MGMA).

The average annual cost of managing type 1 diabetes has skyrocketed, with the rising cost of insulin being a main contributor, according to a new issue brief from the Health Care Cost Institute.